HFS
LGND icon

Hantz Financial Services’s Ligand Pharmaceuticals LGND Stock Holding History

Hantz Financial Services’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Buy
401
+65
+19% +$15.3K ﹤0.01% 1304
2026
Q1 		$67K Sell
336
-18
-5% -$3.56K ﹤0.01% 1442
2025
Q4 		$67K Buy
354
+189
+115% +$36.3K ﹤0.01% 1304
2025
Q3 		$29K Buy
165
+52
+46% +$7.73K ﹤0.01% 1434
2025
Q2 		$13K Buy
113
+53
+88% +$5.67K ﹤0.01% 1429
2025
Q1 		$6K Sell
60
-7,767
-99% -$878K ﹤0.01% 1112
2024
Q4 		$839K Buy
+7,827
New +$885K 0.01% 451

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hantz Financial Services's LGND Position: Q2 2026 in Review

Hantz Financial Services increased its Ligand Pharmaceuticals (LGND) stake by 19% in Q2 2026, buying an estimated $15.3K and bringing the position to 401 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Hantz Financial Services first reported a position in LGND in Q4 2024 and has held it in 7 quarters since. The position peaked at $839K in Q4 2024. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Hantz Financial Services held 401 shares of Ligand Pharmaceuticals worth $127K as of Q2 2026.
  • Hantz Financial Services bought 65 Ligand Pharmaceuticals shares in Q2 2026, an estimated $15.3K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1304 holding.
  • Hantz Financial Services first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Hantz Financial Services's Ligand Pharmaceuticals position peaked at $839K in Q4 2024.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.